NCT04068194: Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Serine-Threonine Kinase Inhibitor, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for phase 1
Exclusions: Patients with symptomatic, untreated, uncontrolled central nervous system (CNS)/leptomeningeal disease – see trial for details; Patients who received prior immunotherapy

Comments are closed.

Up ↑